Christopher Rovaldi
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Keros Therapeutics, Inc. (KROS)
SEC 8-K
Current2024-07-01–present
-
Current
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Keros Therapeutics, Inc. (KROS) | President and Chief Operating Officer | $539,231 | $6,975,416 |
| 2023 | Keros Therapeutics, Inc. (KROS) | President and Chief Operating Officer | $500,000 | $4,688,165 |
| 2022 | Keros Therapeutics, Inc. (KROS) | President and Chief Operating Officer | $435,352 | $4,247,354 |
Recent activity
No earnings-call appearances or filed executive changes recorded yet.